Clinical Trial Update: A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 pharmacological study evaluating YM155 after intravenous infusion in patients with advanced cancer. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• YM155 (Sepantronium bromide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Cancer | Phase 1 | Status: COMPLETED